This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the exams for this article:
 Pediatrics Test 4: Trauma/Infection/Neuromuscular
CME 1: January, February, March 2004
Right arrow Letters to the Editor: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Letters to the Editor are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowReprints and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alman, B. A.
Right arrow Articles by Biggar, W. D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Alman, B. A.
Right arrow Articles by Biggar, W. D.
Related Collections
Right arrow Pediatrics
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Technorati  
What's this?
The Journal of Bone and Joint Surgery (American) 86:519-524 (2004)
© 2004 The Journal of Bone and Joint Surgery, Inc.

Steroid Treatment and the Development of Scoliosis in Males with Duchenne Muscular Dystrophy

Benjamin A. Alman, MD, FRCSC1, S. Naweed Raza1 and W. Douglas Biggar, MD, FRCPC2

1 Department of Surgery and Program in Developmental Biology, The Hospital for Sick Children, 555 University Avenue, Toronto, ON M5G 1X8, Canada. E-mail address for B.A. Alman: benjamin.alman{at}sickkids.ca
2 Bloorview MacMillan Children's Centre, 350 Rumsey Road, Toronto, ON M4G 1R8, Canada

Investigation performed at the Bloorview MacMillan Children's Centre, The Hospital for Sick Children, and the University of Toronto, Toronto, Ontario, Canada

The authors did not receive grants or outside funding in support of their research or preparation of this manuscript. They did not receive payments or other benefits or a commitment or agreement to provide such benefits from a commercial entity. No commercial entity paid or directed, or agreed to pay or direct, any benefits to any research fund, foundation, educational institution, or other charitable or nonprofit organization with which the authors are affiliated or associated.

Background: Scoliosis due to progressive muscle weakness occurs in almost all males with Duchenne muscular dystrophy, and it progresses relentlessly. Previous studies have shown that corticosteroid treatment slows the decline in muscle strength and stabilizes muscle strength in patients with this disease. We hypothesized that steroids may also attenuate the development of scoliosis. The purpose of this study was to compare the prevalence of scoliosis in male patients with Duchenne muscular dystrophy who received steroids with a control group of such patients who did not.

Methods: A group of seven to ten-year-old boys with Duchenne muscular dystrophy who were able to walk were enrolled in a nonrandomized comparative study to determine the effect of deflazacort (a derivative of prednisone) on muscle strength and pulmonary function. Thirty patients were treated with deflazacort (treatment group), and twenty-four were not (control group). The patients were matched for age and pulmonary function at baseline. To assess the development of scoliosis, the patients in each group were followed for at least five years. Survival curves were plotted to determine the chance of scoliosis of ≥20° developing. The difference between the groups with respect to the chance of scoliosis developing was determined with Kaplan-Meier analysis.

Results: A curve of ≥20° developed during the follow-up period in sixteen (67%) of the twenty-four patients in the control group but in only five (17%) of the thirty patients in the treatment group. Fifteen of the twenty-four patients in the control group underwent spine surgery, at a mean age of thirteen years, whereas only five of the thirty patients in the treatment group underwent spine surgery, at a mean age of fifteen years. Kaplan-Meier analysis demonstrated a significant difference between the two groups with regard to development of scoliosis of ≥20° (p < 0.001). Cataracts developed in ten patients in the treatment group, and stress fractures developed in three patients in the treatment group. Patients in the treatment group weighed a mean of 3.7 kg more than did those in the control group.

Conclusions: Steroid treatment slows the progression of scoliosis in males with Duchenne muscular dystrophy; however, longer-term evaluation will be necessary to determine if the treatment prevents the development of scoliosis or just delays its onset. At the very least, steroid treatment delays the need for spinal surgery.

Level of Evidence: Therapeutic study, Level II-1 (prospective cohort study). See Instructions to Authors for a complete description of levels of evidence.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 NeurologyHome page
W. M. King, R. Ruttencutter, H. N. Nagaraja, V. Matkovic, J. Landoll, C. Hoyle, J. R. Mendell, and J. T. Kissel
Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy
Neurology, May 8, 2007; 68(19): 1607 - 1613.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
L. A. Karol
Scoliosis in Patients with Duchenne Muscular Dystrophy
J. Bone Joint Surg. Am., February 1, 2007; 89(suppl_1): 155 - 162.
[Full Text] [PDF]

Home page
 Pediatr. Rev.Home page
W. D. Biggar
Duchenne Muscular Dystrophy
Pediatr. Rev., March 1, 2006; 27(3): 83 - 88.
[Full Text] [PDF]

Home page
 JBJSHome page
M. S. Kocher and P. O. Newton
What's New in Pediatric Orthopaedics
J. Bone Joint Surg. Am., May 1, 2005; 87(5): 1171 - 1179.
[Full Text] [PDF]